Effects of Anesthesia on Maternal and Fetal Oxidative Stress During Cesarean Delivery

November 5, 2026 updated by: University of Banja Luka

The Impact of Target-Controlled Infusion of Propofol on Fetal Oxidative Stress During Anesthesia for Cesarean Section

Oxidative stress occurs when the production of reactive molecules exceeds the body's antioxidant defenses. Pregnancy is associated with physiological changes that may increase oxidative stress in both the mother and fetus. The type of anesthesia used during cesarean delivery may influence this process.

This study aimed to investigate whether general anesthesia using target-controlled infusion (TCI) of propofol affects maternal and fetal oxidative stress compared with spinal anesthesia and general anesthesia using thiopental and sevoflurane.

A total of 90 healthy pregnant women undergoing elective cesarean delivery were included in this prospective study. Participants were divided into three groups of 30: spinal anesthesia, propofol-based general anesthesia, and thiopental-sevoflurane general anesthesia.

Maternal venous blood, umbilical venous blood, and placental tissue samples were collected to assess biochemical markers of oxidative stress and antioxidant defense. Clinical and anesthesia-related data were also recorded.

The study was designed to compare oxidative stress markers across the three anesthesia techniques and evaluate the potential antioxidant effects of propofol on the mother and fetus.

Study Overview

Detailed Description

This prospective, open-label clinical study was conducted at the University Clinical Centre of the Republic of Srpska in Banja Luka, Bosnia and Herzegovina, to investigate the effects of different anesthetic techniques on maternal and fetal oxidative stress during elective cesarean delivery.

The study included 90 pregnant women with uncomplicated pregnancies undergoing elective cesarean delivery. Participants were allocated to three groups of 30 according to the anesthetic technique: spinal anesthesia (Group S), general anesthesia with target-controlled infusion of propofol (Group P), and general anesthesia with thiopental induction followed by sevoflurane maintenance (Group TS).

Maternal venous blood, umbilical venous blood, and placental tissue samples were collected to assess oxidative stress and antioxidant defense mechanisms. The biochemical analyses included markers of lipid peroxidation, reactive oxygen species, and antioxidant activity, including thiobarbituric acid-reactive substances (TBARS), nitrites, hydrogen peroxide, superoxide anion, superoxide dismutase (SOD), reduced glutathione (GSH), and catalase (CAT).

Maternal hemodynamic parameters, anesthetic drug administration, neonatal clinical outcomes, and postoperative maternal outcomes were also evaluated.

The study aimed to compare oxidative stress responses across the three anesthetic techniques and investigate whether propofol-based total intravenous anesthesia provides potential antioxidant benefits in the maternal-placental-fetal system.

Study Type

Interventional

Enrollment (Actual)

90

Phase

  • Phase 4

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Republika Srpska
      • Banja Luka, Republika Srpska, Bosnia and Herzegovina, 78000
        • University Clinical Centre of the Republic of Srpska

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Description

Inclusion Criteria:

  • Uncomplicated singleton pregnancy.
  • Estimated fetal weight greater than 2500 g.
  • Scheduled elective cesarean delivery.
  • Written informed consent to participate in the study.

Exclusion Criteria:

  • Emergency cesarean delivery.
  • Thrombophilia.
  • Hypertensive disorders of pregnancy.
  • Diabetes mellitus.
  • Maternal smoking.
  • Intrauterine fetal growth restriction (IUGR).
  • Fetal malformations.
  • Intrauterine fetal death.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Arm 1 - Spinal anesthesia

Thirty women undergoing elective cesarean section under spinal anesthesia.

Spinal anesthesia administered for elective cesarean section as part of routine clinical care.

Experimental: Arm 2 - Propofol TCI

Thirty women undergoing elective cesarean section under general anesthesia using target-controlled infusion of propofol.

General anesthesia using target-controlled infusion of propofol for elective cesarean section.

Active Comparator: Arm 3 - Thiopental-Sevoflurane

Thirty women undergoing elective cesarean section under general anesthesia with thiopental induction and sevoflurane maintenance.

Thiopental was administered intravenously for induction of general anesthesia in women undergoing elective cesarean section. Anesthesia was subsequently maintained with sevoflurane.

Sevoflurane was administered by inhalation for maintenance of general anesthesia during elective cesarean section, following intravenous induction with thiopental.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Maternal Plasma TBARS Concentration
Time Frame: Before anesthesia, during cesarean delivery, and 2 hours postoperatively.

Thiobarbituric acid-reactive substances (TBARS), an indicator of lipid peroxidation, measured in maternal plasma. Concentrations were compared across the three anesthesia groups and assessed at three perioperative time points. Values are expressed in mmol/L.

Before anesthesia, during cesarean delivery, and 2 hours postoperatively.
Umbilical Cord Venous Plasma TBARS Concentration
Time Frame: At delivery (umbilical cord venous blood sampling).

Thiobarbituric acid-reactive substances (TBARS), an indicator of lipid peroxidation, measured in umbilical cord venous plasma. Concentrations were compared across the three anesthesia groups. Values are expressed in mmol/L.

At delivery (umbilical cord venous blood sampling).
Placental Tissue TBARS Concentration
Time Frame: At delivery, immediately following placental removal.

Thiobarbituric acid-reactive substances (TBARS), an indicator of lipid peroxidation, measured in placental tissue homogenates. Concentrations were compared across the three anesthesia groups. Values are expressed in µmol/g of tissue.

At delivery, immediately following placental removal.
Maternal Plasma Hydrogen Peroxide (H2O2) Concentration
Time Frame: Before anesthesia, after delivery and placental removal, and 2 hours postoperatively.

Hydrogen peroxide (H2O2), a marker of oxidative stress, measured in maternal plasma. Concentrations were compared across the three anesthesia groups at three perioperative time points. Values are expressed in nmol/mL.

Before anesthesia, after delivery and placental removal, and 2 hours postoperatively.
Umbilical Cord Venous Plasma Hydrogen Peroxide (H2O2) Concentration
Time Frame: At delivery (umbilical cord venous blood sampling).

Hydrogen peroxide (H2O2), a marker of oxidative stress, measured in umbilical cord venous plasma. Concentrations were compared across the three anesthesia groups. Values are expressed in nmol/mL.

At delivery (umbilical cord venous blood sampling).
Maternal Plasma Superoxide Anion (O2-) Concentration
Time Frame: Before anesthesia, after delivery and placental removal, and 2 hours postoperatively.

Superoxide anion (O2-), a reactive oxygen species and marker of oxidative stress, measured in maternal plasma. Concentrations were compared across the three anesthesia groups at three perioperative time points. Values are expressed in nmol/mL.

Before anesthesia, after delivery and placental removal, and 2 hours postoperatively.
Umbilical Cord Venous Plasma Superoxide Anion (O2-) Concentration
Time Frame: At delivery (umbilical cord venous blood sampling).

Superoxide anion (O2-), a reactive oxygen species and marker of oxidative stress, measured in umbilical cord venous plasma. Concentrations were compared across the three anesthesia groups. Values are expressed in nmol/mL.

At delivery (umbilical cord venous blood sampling).
Maternal Plasma Nitrite (NO2-) Concentration
Time Frame: Before anesthesia, after delivery and placental removal, and 2 hours postoperatively.

Nitrite (NO2-), an indicator of nitric oxide metabolism, measured in maternal plasma. Concentrations were compared across the three anesthesia groups at three perioperative time points. Values are expressed in nmol/mL.

Before anesthesia, after delivery and placental removal, and 2 hours postoperatively.
Umbilical Cord Venous Plasma Nitrite (NO2-) Concentration
Time Frame: At delivery (umbilical cord venous blood sampling).

Nitrite (NO2-), an indicator of nitric oxide metabolism, measured in umbilical cord venous plasma. Concentrations were compared across the three anesthesia groups. Values are expressed in nmol/mL.

At delivery (umbilical cord venous blood sampling).
Maternal Erythrocyte Superoxide Dismutase (SOD) Activity
Time Frame: Before anesthesia, after delivery and placental removal, and 2 hours postoperatively.

Superoxide dismutase (SOD) activity, an indicator of enzymatic antioxidant defense, measured in maternal erythrocyte lysates. Activity was compared across the three anesthesia groups at three perioperative time points. Values are expressed in U/g Hgb × 10³.

Before anesthesia, after delivery and placental removal, and 2 hours postoperatively.
Umbilical Cord Venous Erythrocyte Superoxide Dismutase (SOD) Activity
Time Frame: At delivery (umbilical cord venous blood sampling).

Superoxide dismutase (SOD) activity, an indicator of enzymatic antioxidant defense, measured in erythrocyte lysates from umbilical cord venous blood. Activity was compared across the three anesthesia groups. Values are expressed in U/g Hgb × 10³.

At delivery (umbilical cord venous blood sampling).
Placental Tissue Superoxide Dismutase (SOD) Activity
Time Frame: At delivery, following placental removal.

Superoxide dismutase (SOD) activity, an indicator of enzymatic antioxidant defense, measured in placental tissue homogenates. Activity was compared across the three anesthesia groups. Values are expressed in U/g of tissue.

At delivery, following placental removal.
Maternal Erythrocyte Reduced Glutathione (GSH) Concentration
Time Frame: Before anesthesia, after delivery and placental removal, and 2 hours postoperatively.

Reduced glutathione (GSH), a non-enzymatic antioxidant involved in cellular defense against oxidative stress, measured in maternal erythrocyte lysates. Concentrations were compared across the three anesthesia groups at three perioperative time points. Values are expressed in nmol/mL RBC.

Before anesthesia, after delivery and placental removal, and 2 hours postoperatively.
Umbilical Cord Venous Erythrocyte Reduced Glutathione (GSH) Concentration
Time Frame: At delivery (umbilical cord venous blood sampling).

Reduced glutathione (GSH), a non-enzymatic antioxidant involved in cellular defense against oxidative stress, measured in erythrocyte lysates from umbilical cord venous blood. Concentrations were compared across the three anesthesia groups. Values are expressed in nmol/mL RBC.

At delivery (umbilical cord venous blood sampling).
Placental Tissue Reduced Glutathione (GSH) Concentration
Time Frame: At delivery, following placental removal.

Reduced glutathione (GSH), a non-enzymatic antioxidant involved in cellular defense against oxidative stress, measured in placental tissue homogenates. Concentrations were compared across the three anesthesia groups. Values are expressed in nmol/g of tissue.

At delivery, following placental removal.
Maternal Erythrocyte Catalase (CAT) Activity
Time Frame: Before anesthesia, after delivery and placental removal, and 2 hours postoperatively.

Catalase (CAT) activity, an indicator of enzymatic antioxidant defense, measured in maternal erythrocyte lysates. Activity was compared across the three anesthesia groups at three perioperative time points. Values are expressed in U/g Hgb × 10³.

Before anesthesia, after delivery and placental removal, and 2 hours postoperatively.
Umbilical Cord Venous Erythrocyte Catalase (CAT) Activity
Time Frame: At delivery (umbilical cord venous blood sampling).

Catalase (CAT) activity, an indicator of enzymatic antioxidant defense, measured in erythrocyte lysates from umbilical cord venous blood. Activity was compared across the three anesthesia groups. Values are expressed in U/g Hgb × 10³.

At delivery (umbilical cord venous blood sampling).
Placental Tissue Catalase (CAT) Activity
Time Frame: At delivery, following placental removal.

Catalase (CAT) activity, an indicator of enzymatic antioxidant defense, measured in placental tissue homogenates. Activity was compared across the three anesthesia groups. Values are expressed in U/g of tissue.

At delivery, following placental removal.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Umbilical Cord Blood pH
Time Frame: At delivery (umbilical cord blood sampling).

Umbilical cord blood pH measured by blood gas analysis immediately after delivery to assess neonatal acid-base status. Values were compared across the three anesthesia groups. pH is dimensionless.

At delivery (umbilical cord blood sampling).
Umbilical Cord Blood Partial Pressure of Oxygen (pO₂)
Time Frame: At delivery (umbilical cord blood sampling).

Partial pressure of oxygen (pO₂) measured in umbilical cord blood by blood gas analysis to assess neonatal oxygenation at birth. Values were compared across the three anesthesia groups. Results are expressed in mmHg.

At delivery (umbilical cord blood sampling).
Umbilical Cord Blood Partial Pressure of Carbon Dioxide (pCO₂)
Time Frame: At delivery (umbilical cord blood sampling).

Partial pressure of carbon dioxide (pCO₂) measured in umbilical cord blood by blood gas analysis to assess neonatal acid-base status at birth. Values were compared across the three anesthesia groups. Results are expressed in mmHg.

At delivery (umbilical cord blood sampling).
Umbilical Cord Blood Base Excess (BE)
Time Frame: At delivery (umbilical cord blood sampling).

Base excess (BE) measured in umbilical cord blood by blood gas analysis to assess neonatal metabolic acid-base status at birth. Values were compared across the three anesthesia groups. Results are expressed in mmol/L.

At delivery (umbilical cord blood sampling).
Umbilical Cord Blood Lactate Concentration
Time Frame: At delivery (umbilical cord blood sampling).

Lactate concentration measured in umbilical cord blood by blood gas analysis to assess neonatal metabolic status at birth. Values were compared across the three anesthesia groups. Results are expressed in mmol/L.

At delivery (umbilical cord blood sampling).
Maternal Venous Blood pH
Time Frame: Intraoperatively, during cesarean delivery.

Maternal venous blood pH measured by blood gas analysis during cesarean delivery to assess maternal acid-base status. Values were compared across the three anesthesia groups. pH is dimensionless.

Intraoperatively, during cesarean delivery.
Maternal Venous Blood Partial Pressure of Oxygen (pO₂)
Time Frame: Intraoperatively, during cesarean delivery.

Partial pressure of oxygen (pO₂) measured in maternal venous blood by blood gas analysis during cesarean delivery to assess maternal venous oxygenation. Values were compared across the three anesthesia groups. Results are expressed in mmHg.

Intraoperatively, during cesarean delivery.
Maternal Venous Blood Partial Pressure of Carbon Dioxide (pCO₂)
Time Frame: Intraoperatively, during cesarean delivery.

Partial pressure of carbon dioxide (pCO₂) measured in maternal venous blood by blood gas analysis during cesarean delivery to assess maternal acid-base and respiratory status. Values were compared across the three anesthesia groups. Results are expressed in mmHg.

Intraoperatively, during cesarean delivery.
Intraoperatively, during cesarean delivery.
Time Frame: Intraoperatively, during cesarean delivery.

Lactate concentration measured in maternal venous blood by blood gas analysis during cesarean delivery to assess maternal metabolic status. Values were compared across the three anesthesia groups. Results are expressed in mmol/L.

Intraoperatively, during cesarean delivery.
Maternal Venous Blood Base Excess (BE)
Time Frame: Intraoperatively, during cesarean delivery.

Base excess (BE) measured in maternal venous blood by blood gas analysis during cesarean delivery to assess maternal metabolic acid-base status. Values were compared across the three anesthesia groups. Results are expressed in mmol/L.

Intraoperatively, during cesarean delivery.
Maternal White Blood Cell Count (WBC)
Time Frame: Intraoperatively and 2 hours after delivery.

Maternal white blood cell (WBC) count measured in venous blood as part of a complete blood count to assess maternal hematological status. Values were compared across the three anesthesia groups. Results are expressed in ×10⁹/L.

Intraoperatively and 2 hours after delivery.
Maternal C-Reactive Protein (CRP) Concentration
Time Frame: Intraoperatively and 2 hours after delivery.

Maternal C-reactive protein (CRP) concentration measured in venous blood to assess maternal inflammatory status. Values were compared across the three anesthesia groups. Results are expressed in mg/L.

Intraoperatively and 2 hours after delivery.
Intraoperatively and 2 hours after delivery.
Time Frame: 48-72 hours after birth.

Neonatal white blood cell (WBC) count measured in venous blood as part of a complete blood count to assess neonatal hematological status. Values were compared across the three maternal anesthesia groups. Results are expressed in ×10⁹/L.

48-72 hours after birth.
Neonatal C-Reactive Protein (CRP) Concentration
Time Frame: 48-72 hours after birth.

Neonatal C-reactive protein (CRP) concentration measured in venous blood to assess neonatal inflammatory status. Values were compared across the three maternal anesthesia groups. Results are expressed in mg/L.

48-72 hours after birth.
Maternal Mean Arterial Pressure (MAP)
Time Frame: Before anesthesia (minute 0) and at 2, 4, 6, 8, and 10 minutes after anesthesia initiation, until delivery.

Maternal mean arterial pressure (MAP) was calculated from noninvasively measured systolic and diastolic arterial blood pressure values. Measurements were obtained before anesthesia and at 2-minute intervals after anesthesia initiation. MAP values were compared across the three anesthesia groups and expressed in mmHg.

Before anesthesia (minute 0) and at 2, 4, 6, 8, and 10 minutes after anesthesia initiation, until delivery.
Maternal Heart Rate (HR)
Time Frame: Before anesthesia (minute 0) and at 2, 4, 6, 8, and 10 minutes after anesthesia initiation.

Maternal heart rate (HR) measured by standard intraoperative monitoring before anesthesia and at 2-minute intervals after anesthesia initiation. Measurements were compared across the three anesthesia groups. Results are expressed in beats per minute (bpm).

Before anesthesia (minute 0) and at 2, 4, 6, 8, and 10 minutes after anesthesia initiation.
Patient-Reported Anesthesia-Related Adverse Effects
Time Frame: On the first postoperative day (24 hours after anesthesia).

Anesthesia-related adverse effects were assessed using the Bauer questionnaire on the first postoperative day. Ten symptoms were evaluated: postoperative pain, drowsiness, thirst, hoarseness, sore throat, nausea and vomiting, feeling cold, difficulty concentrating, pain at the anesthetic administration site, and shivering. The outcome was expressed as the number and percentage of patients reporting each adverse effect, separately for each anesthesia group.

On the first postoperative day (24 hours after anesthesia).
Intraoperative Awareness During General Anesthesia
Time Frame: On the first postoperative day (24 hours after anesthesia).

Intraoperative awareness was assessed in patients receiving general anesthesia using the modified Brice questionnaire. Patients were asked about their last memory before anesthesia, first memory after awakening, any recollection of events during surgery, and dreams during anesthesia. The occurrence of reported intraoperative awareness was compared between the propofol TCI and thiopental-sevoflurane groups. The outcome was expressed as the number and percentage of patients reporting intraoperative awareness.

On the first postoperative day (24 hours after anesthesia).
Neonatal Apgar Score at 1 Minute
Time Frame: 1 minute after birth.

Neonatal condition was assessed using the Apgar score at 1 minute after birth. The score evaluates five components: heart rate, respiratory effort, muscle tone, reflex irritability, and skin color. Each component is scored from 0 to 2, resulting in a total score ranging from 0 to 10. Apgar scores were compared across the three maternal anesthesia groups. Higher Apgar scores indicate better neonatal clinical condition.

1 minute after birth.
Neonatal Apgar Score at 5 Minutes
Time Frame: 5 minutes after birth.

Neonatal condition was assessed using the Apgar score at 5 minutes after birth. The score evaluates five components: heart rate, respiratory effort, muscle tone, reflex irritability, and skin color. Each component is scored from 0 to 2, resulting in a total score ranging from 0 to 10. Apgar scores were compared across the three maternal anesthesia groups. Higher Apgar scores indicate better neonatal clinical condition.

5 minutes after birth.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 1, 2022

Primary Completion (Actual)

February 19, 2024

Study Completion (Actual)

February 19, 2024

Study Registration Dates

First Submitted

October 31, 2026

First Submitted That Met QC Criteria

November 5, 2026

First Posted (Actual)

November 12, 2026

Study Record Updates

Last Update Posted (Actual)

November 12, 2026

Last Update Submitted That Met QC Criteria

November 5, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

Individual participant data will not be shared because data sharing was not included in the original study protocol or informed consent procedures.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe